• Mutation; HGNC; HGNC:1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583).
  
• Mutation; HGNC; HGNC:7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583).
  

DOI=10.1093/jnci/59.2.301
Laurie A. Quinn, Linda K. Woods, S.B. Merrick, N.M. Arabasz, George Eugene Moore;
Cytogenetic analysis of twelve human malignant melanoma cell lines.
J. Natl. Cancer Inst. 59:301-307(1977)

PubMed=72600
Brahma Sharma;
In vitro immunization against human tumor cells with tumor cell fractions.
Cancer Res. 37:4660-4668(1977)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Jorgen Fogh, Jens M. Fogh, Thomas Orfeo;
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Jorgen Fogh, William C. Wright, James D. Loveless;
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Jons Ake Espmark, Lena Ahlqvist-Roth, Lena Sarne, Anita Persson;
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=6277475
Richard J. Frampton, Larry J. Suva, John Allan Eisman, David M. Findlay, George Eugene Moore, Jane M. Moseley, Thomas John Martin;
Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture.
Cancer Res. 42:1116-1119(1982)

PubMed=6220172
Nicholas C. Dracopoli, Jorgen Fogh;
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3518877; DOI=10.3109/07357908609038260
Jorgen Fogh;
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3180053
Jeffrey F. Lemontt, Marie Azzaria, Philippe Gros;
Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells.
Cancer Res. 48:6348-6353(1988)

PubMed=9354451
Marina Castellano, Pamela M. Pollock, Marilyn K. Walters, Louise E. Sparrow, Louise M. Down, Brian G. Gabrielli, Peter G. Parsons, Nicholas K. Hayward;
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997)

PubMed=15048078; DOI=10.1038/sj.onc.1207563
Sandra Pavey, Peter Johansson, Leisl Packer, Jennifer Taylor, Mitchell S. Stark, Pamela M. Pollock, Graeme J. Walker, Glen M. Boyle, Ursula Harper, Sarah-Jane Cozzi, Katherine Hansen ...Show all 20 authors... , Laura Yudt, Chris Schmidt, Peter Hersey, Kay Adrian Oswald Ellem, Michael G.E. O'Rourke, Peter G. Parsons, Paul S. Meltzer, Markus Ringner, Nicholas K. Hayward; Show fewer authors
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004)

PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Mitchell S. Stark, Nicholas K. Hayward;
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007)

PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Ken Dutton-Regester, Darryl Irwin, Priscilla Hunt, Lauren G. Aoude, Varsha Tembe, Gulietta M. Pupo, Cathy Lanagan, Candace D. Carter, Linda O'Connor, Michael O'Rourke, Richard Anthony Scolyer ...Show all 15 authors... , Graham J. Mann, Christopher W. Schmidt, Adrian Herington, Nicholas K. Hayward; Show fewer authors
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012)